AML awareness day ..21 April 2018
Earlier today it was great to see the note - copied-in below- from Dr Lou De Gennaro (President & CEO of the Leukemia & Lymphoma Society) reminding us (a) of AML awareness day coming up on 21st April, and (b) the groundbreaking Beat AML Master trial that LLS is driving. At a personal level, I have to note that our team at Syneos Health is delighted to be supporting LLS with this groundbreaking clinical trial.
....and it was also inspirational to see the story from this year's Boston Marathon of Mary Shertenlieb - a 3-time cancer/AML survivor - who showed remarkable determination to complete this grueling event. People do amazing things.
We should all applaud and be humbled by folks like Mary, be thankful for the determination and commitment of Lou and the LLS team, and always remember to recognize the physicians, nurses and support teams - caregivers of all kinds - who dedicate their time to clinical research and practice in the interests of patients with AML.
FROM: Louis J. DeGennaro, Ph.D. - President and CEO, LLS AML Awareness Day is this Saturday, April 21, The Leukemia & Lymphoma Society (LLS) works tirelessly every day of the year to lead our ambitious attack against this disease and give new hope to patients and their families.
Acute myeloid leukemia (AML) is a complex, rapidly progressing cancer that has seen few advances in treatment even as therapies for other blood cancers have taken remarkable leaps forward. Since the 1960s, five-year survival rates for many blood cancers have doubled, tripled and even quadrupled. Today, only one in four AML patients survives five years after diagnosis.
Through our Beat AML? Master Clinical Trial, we’re taking a precision medicine approach to treatment to give the right therapy to the right patient at the right time. To achieve this, we’re uniting the most innovative minds in the scientific and medical community, from scientists at top cancer centers and the U.S. Food and Drug Administration (FDA) to multiple drug companies and a cutting-edge genomics company.
By matching investigational therapies with a patient’s specific AML subtype, our goal is to revolutionize how this disease is treated and bring better therapies to patients faster. We’re proud to say that more than 200 patients are enrolled at eight prestigious cancer centers across the country, and this momentum will only intensify as more patients and centers join us soon.
Along with the trial, we continue to invest in the most promising AML science, and provide education and support at every step of the patient and caregiver experience. Learn more about our unwavering commitment to achieving AML cures.